ID   Caf 10
AC   CVCL_1H12
SY   caf 10; Caf10; CAF10
DR   Wikidata; Q54808360
RX   Patent=US6358511;
RX   PubMed=11192295;
RX   PubMed=11752148;
CC   Doubling time: 3 days (Patent=US6358511).
CC   Transformant: NCBI_TaxID; 10381; Saimiriine herpesvirus 2 (Herpesvirus saimiri).
CC   Donor information: Established from a HIV-1 infected child with rapid disease progression.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Children
CA   Transformed cell line
DT   Created: 08-07-15; Last updated: 29-06-23; Version: 7
//
RX   Patent=US6358511;
RA   Klotman M.E., Mosoian A., Teixeira A.;
RT   "Inhibitors of HIV infection.";
RL   Patent number US6358511, 19-Mar-2002.
//
RX   PubMed=11192295; DOI=10.1089/vim.2000.13.481;
RA   Mosoian A., Teixeira A., Caron E., Piwoz J.A., Klotman M.E.;
RT   "CD8+ cell lines isolated from HIV-1-infected children have potent
RT   soluble HIV-1 inhibitory activity that differs from beta-chemokines.";
RL   Viral Immunol. 13:481-495(2000).
//
RX   PubMed=11752148; DOI=10.1128/JVI.76.2.569-581.2002;
RA   Chang T.L.-Y., Mosoian A., Pine R., Klotman M.E., Moore J.P.;
RT   "A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human
RT   immunodeficiency virus type 1 replication through STAT1 activation.";
RL   J. Virol. 76:569-581(2002).
//